One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
Healing a fractured world: mRNA therapies to take centre stage?
doi : 10.1016/S1470-2045(25)00558-3
Volume 26, Issue 10, October 2025, Page 1261
Sequential metastasis-directed therapy in renal-cell carcinoma: promising, but unproven without randomised evidence
More is not always more for older patients with multiple myeloma
A GOLP rush in biliary tract cancer: early promise in the quest for curative surgery
Neoadjuvant approaches in non-metastatic pancreatic cancer: where do we stand?
Principles for advancing healthy workplace cultures: an ASCO–COSA–ECO joint statement
CONTACT-02: limited clinical benefit and a suboptimal control group
CONTACT-02: limited clinical benefit and a suboptimal control group – Authors' reply
Advancing patient-centred CINV care: gaps in olanzapine trial design
Advancing patient-centred CINV care: gaps in olanzapine trial design – Authors’ reply
AJCC9V classification for HPV-positive oropharyngeal carcinoma – Authors' reply
Experts warn cuts to mRNA contracts and Medicaid will hit cancer care and research
Australia invests in cancer research grants led by First Nations communities
UK cancer research impeded by visa fees for international researchers
Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study
TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial
Genetic modification of the AJCC classification of papillary thyroid cancer: an international, multicentre, retrospective cohort study
Health-care transitions for young people living beyond childhood and adolescent cancer: recommendations from the EU–CAYAS–NET consortium
Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium
Digital health and artificial intelligence innovations for oncology in sub-Saharan Africa
Challenges for Chinese innovative cancer drugs in going global: insights from multiregional clinical trials
